![]() |
Name |
(1R,4R,5S)-8-(hydroxymethyl)-1,7-dimethyl-4-propan-2-ylbicyclo[3.2.1]oct-6-ene-6-carbaldehyde
|
Molecular Formula | C15H24O2 | |
IUPAC Name* |
(1R,4R,5S)-8-(hydroxymethyl)-1,7-dimethyl-4-propan-2-ylbicyclo[3.2.1]oct-6-ene-6-carbaldehyde
|
|
SMILES |
CC1=C([C@H]2[C@H](CC[C@@]1(C2CO)C)C(C)C)C=O
|
|
InChI |
InChI=1S/C15H24O2/c1-9(2)11-5-6-15(4)10(3)12(7-16)14(11)13(15)8-17/h7,9,11,13-14,17H,5-6,8H2,1-4H3/t11-,13?,14-,15+/m1/s1
|
|
InChIKey |
JNDNSKMAFGPBFU-JZIBPQBNSA-N
|
|
Synonyms |
Helminthosporol
|
|
CAS | NA | |
PubChem CID | 6326281 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 236.35 | ALogp: | 2.6 |
HBD: | 1 | HBA: | 2 |
Rotatable Bonds: | 3 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 37.3 | Aromatic Rings: | 2 |
Heavy Atoms: | 17 | QED Weighted: | 0.76 |
Caco-2 Permeability: | -4.429 | MDCK Permeability: | 0.00001570 |
Pgp-inhibitor: | 0 | Pgp-substrate: | 0.002 |
Human Intestinal Absorption (HIA): | 0.008 | 20% Bioavailability (F20%): | 0.013 |
30% Bioavailability (F30%): | 0.011 |
Blood-Brain-Barrier Penetration (BBB): | 0.692 | Plasma Protein Binding (PPB): | 90.44% |
Volume Distribution (VD): | 1.093 | Fu: | 7.24% |
CYP1A2-inhibitor: | 0.287 | CYP1A2-substrate: | 0.5 |
CYP2C19-inhibitor: | 0.072 | CYP2C19-substrate: | 0.903 |
CYP2C9-inhibitor: | 0.068 | CYP2C9-substrate: | 0.098 |
CYP2D6-inhibitor: | 0.012 | CYP2D6-substrate: | 0.104 |
CYP3A4-inhibitor: | 0.388 | CYP3A4-substrate: | 0.698 |
Clearance (CL): | 6.288 | Half-life (T1/2): | 0.492 |
hERG Blockers: | 0.013 | Human Hepatotoxicity (H-HT): | 0.089 |
Drug-inuced Liver Injury (DILI): | 0.104 | AMES Toxicity: | 0.111 |
Rat Oral Acute Toxicity: | 0.421 | Maximum Recommended Daily Dose: | 0.092 |
Skin Sensitization: | 0.395 | Carcinogencity: | 0.565 |
Eye Corrosion: | 0.817 | Eye Irritation: | 0.86 |
Respiratory Toxicity: | 0.975 |